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120 Poster Session-IIMethods: 20 pts with hematological malignancies were given
MSC (1–2  10E6 cells/kg) from third party donors a few hours be-
fore PBSC from HLA-mismatched unrelated donors, after condi-
tioning with 2 Gy TBI and fludarabine 90 mg/m2. Postgrafting
immunosuppression included tacrolimus (day -3 to 1180; tapered
by day 1365) and mycophenolate mofetil (tid days 0 to 142).
HLA-compatibility was assessed at the HLA-A, -B, -C, -DRBI and
DQBI loci. 12 pairs were mismatched for at least one HLA class I an-
tigen (including 4 pairs who were also mismatched for 1 HLA-class
II antigens (n 5 3) or 1 HLA-class I allele (n 5 1)), 1 pair was mis-
matched for 2 HLA class II alleles, and 7 pairs were mismatched
for a single HLA class I (n 5 4) or HLA class II (n 5 3) alleles.
Results: Median follow-up for surviving pts was 219 (range, 13–
519) days, and 17 pts are already evaluable for day 100 nonrelapse mor-
tality (primary endpoint). Thus far, 1 patient with secondary AML had
primary graft rejection, while the remaining pts had sustained engraft-
ment. Median donor T-cell chimerism levels on days 28, 100, 180 and
365 after HCT were 91%, 97%, 96%, and 98%, respectively. Grade
II, III and IV acute GVHD were seen in 4, 2 and 0 pts, respectively.
Two pts died of non-relapse causes on days 74 and 114 after HCT,
while 3 pts died of disease progression. Projected 1-yr overall and pro-
gression-free survivals were 74% and 62%, respectively.
Conclusions: HLA-mismatched nonmyeloablative HCT with
MSC co-infusion appeared to be safe. These encouraging results,
suggesting improved outcomes compared to similar pts not co-
infused with MSC, should be confirmed in a larger multicenter study.
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ANTITHYMOCYTE GLOBULINS (ATG) AS PART OF THE MYELOABLATIVE
CONDITIONING (MAC) REGIMEN CAN REDUCE THE RISK OF SEVERE
GRAFT-VS.-HOST DISEASE (GVHD) AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLO-SCT) FROM MATCHED-UNRELATED DONORS
(MUD) [A SFGM-TC STUDY]
Mohty, M.1, Balere, M.L.2, Socie, G.3, Milpied, N.4, Ifrah, N.5,
Kuentz, M.6, Harousseau, J.L.1, Vernant, J.P.7, Michallet, M.8,
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Here, we report the results of a multicenter retrospective study an-
alyzing the effect of ATG, incorporated within the MAC regimen for
MUD-transplants in leukemic patients. The purpose of the study was
to compare the incidence and severity of acute and chronic GVHD as
well as overall outcome. 171 adult patients with acute leukemia and
MDS, for whom detailed allelic HLA typing (4 digits) was available,
were included. 81% of patients were transplanted from 10/10 allelic
MUD, and 19% from a MUD with at least one allelic difference. 120
patients (70%) did not receive ATG (‘‘no-ATG’’ group), while 51 pa-
tients received ATG (‘‘ATG’’ group; Thymoglobuline*, Genzyme in
all cases) as part of the MAC regimen. Except for a significantly higher
number of allelic differences between recipient and donor (33% vs.
13%; P 5 0.002), the ‘‘no-ATG’’ and ‘‘ATG’’ groups were strictly
comparable. With a median follow-up of 30.3 (range, 2.6–68.1)
months, grade 0–1 and 2–4 acute GVHD occurred in 74 (46%) and
88 patients (54%) respectively, with grade 3–4 acute GVHD being
significantly lower in the ‘‘ATG’’ group (18% vs. 32%; P 5 0.04).
Limited and extensive chronic GVHD were observed in 22 and
25% of assessable patients respectively, with extensive chronic
GVHD being significantly lower in the ‘‘ATG’’ group (5% vs.
33%; P 5 0.001). Interestingly, patients from the ‘‘ATG’’ group
had a higher incidence of limited chronic GVHD (33% vs. 18%;
P5 0.06). Moreover, infection-related mortality was comparable be-
tween both groups (23% vs. 27%, P5NS). Also, NRM was compa-
rable between both groups (30% vs. 29%; P 5NS). In multivariate
analysis, an HLA allelic mismatch and the non-use of ATG were as-
sociated with an increased risk of grade 3–4 acute GVHD (RR52.80,
95%CI, 1.5–5.3, P5 0.001; and RR5 2.4, 95%CI, 1.1–5.0, P5 0.02
respectively). Similarly, multivariate analysis showed that the absence
of use of ATG was the unique parameter associated with an increasedrisk of extensive chronic GVHD (RR 5 6.9; 95%CI, 1.7–29.0, P 5
0.008). Finally, LFS and OS at 2 years were not significantly different
between the ‘‘no-ATG’’ and ‘‘ATG’’ group (48.8% vs. 41.3%, P 5
NS; and 53.6% vs. 54.3%, P5NS; respectively). These results sug-
gest a global long-term beneficial effect of ATG when used as part of
the MAC regimen prior to allo-SCT from MUD (especially in the
HLA mismatch setting). Such protective effect of ATG against severe
GVHD can be likely achieved without an increased risk of infections
or leukemia recurrence.335
HUMAN MEMORY T CELL S ELICIT DECREASED CYTOTOXICITY AGAINST
ALLOGENEIC TARGETS
Zheng, Q., Deoliveira, D., Chao, N.J., Chen, B.J. Duke University Med-
ical Center, Durham, NC
Several groups have independently demonstrated that memory T
cells do not induce graft-versus-host disease in several different ani-
mal models. To test whether the same concept applies to humans, we
compared the ability of memory T cells to respond to alloantigens
with that of naive T cells. Purified T cells were first obtained from
peripheral blood from healthy donors and then separated into mem-
ory and naive T cell subsets based on the expression of CD45RA
(memory: CD45RA-, naive: CD45RA1). Memory T cells were
then tested for their ability to respond to alloantigens by using sev-
eral standard in vitro assays. In contrast to the mouse data, memory
T cells proliferated equally well as naive T cells did in mixed lympho-
cyte culture. Despite the similar proliferative responses against allo-
antigens as those mediated by naive T cells, these same memory T
cells failed to kill the allogeneic targets. Limiting dilution assay dem-
onstrated that the frequency of allospecific cytotoxicity T cells was
6–68.5 fold less in memory T cells than that in naive T cells. Inter-
leukin 2 was unable to restore the cytotoxicity against alloantigens.
The results from skin explant assay further suggested that, in con-
trast to naive T cells, memory T cells might not be able to induce
graft-versus-host disease. These data suggest that human memory
T cells contain less alloantigen-specific cytotoxicity T cells and
may not cause graft-versus-host disease upon in vivo transfer. Since
clinical grade antibody is now available, this approach will soon be
tested in humans for the prevention of graft-versus-host disease.336
PROGNOSTIC FACTORS AND OUTCOMES OF SEVERE GASTROINTESTINAL
GRAFT-VS-HOST DISEASE (GI GVHD) AFTER ALLOGENEIC HEMATOPOI-
ETIC CELL TRANSPLANTATION
Castilla-LLorente, C.1,2, Nash, R.A.1, McDonald, G.B.1, Storer, B.E.1,
Martin, P.J.1 1 Fred Hutchinson Cancer Research Center, University of
Washington, Seattle, WA; 2 Hospital Morales Meseguer, Murcia, Spain
Treatment of severe GI GVHD poses a challenge, as little prog-
ress has been made in developing better treatments, survival remains
poor and it is difficult to know the ultimate severity of GVHD and
the outcome at the onset of symptoms. We reviewed the records of
117 consecutive patients transplanted between 2000–2005 who de-
veloped stages 3–4 GI GVHD. Data were collected for more than
20 parameters including stool volume, abdominal pain, melena, up-
per GI symptoms, serum albumin, number of treatments, visual find-
ings at endoscopy and histopathologic grade of GI biopsies. Clinical
parameters were measured as the peak value during each 14 day pe-
riod starting from 2 weeks before the diagnosis of GI GVHD to the
resolution of symptoms, loss of follow-up or patient death. Median
onset of symptoms was day 29 (range 4 – 135); 11 (9.6%) patients
presented after day 80. Mean daily stool volume at diagnosis was
1831.12 61438.16mL/day. At onset of GI symptoms, 56% of pa-
tients had $ stage 1 skin GVHD and 62% had $ stage 1 liver
GVHD. At onset, 78% had upper GI symptoms and 55% of patients
presented with severe abdominal pain. Within the first 2 weeks after
the diagnosis of GI GVHD, 62 (53%), 37 (31.6%), 4 (3.4%), 13
(11.2%) and 1 (0.8%) patients had a peak GI stage of 4, 3, 2, 1 and
0 respectively. All patients received high dose prednisone/predniso-
lone as initial treatment; 67 received 2nd line therapy; and 32 received
three or more lines of treatment. Non-relapse mortality was 71%
and 41% at 1 year after transplant in patients with steroid-refractory
and steroid-responsive GVHD, respectively. Overall survival was
Poster Session-II 12130% at 1 year after HCT and 26% at 2 years. Adult patients who had
steroid-refractory GVHD within 2 weeks of onset had a 1-year sur-
vival of 16% compared to 88% among steroid refractory pediatric
patients. During the 14 day periods immediately before or after
the onset of GI symptoms, these risk factors for overall mortality
were identified by multivariable analysis.
Risk factors for mortality in 117 patients with stage 3/4 gut
GVHD
Univariate MultivariateHR (95% CI) P-value HR (95% CI) P-valueStage at onset
3 (n544) 1.0 1.0
4 (n573) 2.09 (1.3–3.3) 0.001 1.87 (1.1–3.1) 0.01
Steroid refractory
No (n537) 1.0 1.0
Yes (n580) 2.4 (1.5–3.9) 0.0002 2.11 (1.2–3.6) 0.005
Age at transplant
#18 (n515) 1.0 1.0
$18 (n5102) 3.84 (1.7–8.8) 0.0001 3.64 (1.5–8.7) 0.0008
Bilirrubin
#3.0 (n558) 1.0 1.0
$3 (n559) 2.88 (1.9–4.4) \0.0001 2.52 (1.6–4.0) 0.0001
Albumin
.1.6 (n585) 1.0 1.0
#1.6 (n532) 2.74 (1.7–4.3) \0.0001 1.69 (1.0–2.8) 0.05
Regimen related toxicity
No (n557) 1.0 1.0
Yes (n560) 0.81 (0.5–1.2) 0.33
Upper endoscopy1 (clinical)
0-2 (n565) 1.0 1.0
31 (n511) 2.91 (1.5–5.7) 0.005 2.45 (1.2–5.2) 0.03
Upper endoscopy1 (biopsy)
0-2 (n570) 1.0 1.0
31 (n56) 2.41 (1.0–2.7) 0.07
Lower endoscopy2 (clinical)
0-2 (n535) 1.0 1.0
31 (n511) 1.23 (0.6–2.5) 0.58
Lower endoscopy2 (biopsy)
0-2 (n526) 1.0 1.0
31 (n520) 1.43 (0.7–2.7) 0.28
CT scan30,1 (n528) 1.0 1.0
2 (n512) 0.48 (0.2–1.2) 0.091available in 76 patients (term for missing included in multivariate model)
2available in 46 patients
3available in 40 patients. All covariates are based on the ‘worst’ assess-
ment prior to and including the interval of onset
In a subgroup of patients who underwent endoscopy (N 5 73),
a finding of ulcerated mucosa was predictive of mortality (HR
2.52, p 5 0.02). Within 2 weeks of GI symptom onset, mortality
in patients with GVHD can be predicted by age, jaundice, hypoalbu-
minemia, response to prednisone, and presence of ulcerated mucosa
at endoscopy. More effective early treatment in GI GVHD patients
at risk for mortality is likely to be more useful than salvage therapy
for steroid-refractory patients.337
TO AUGMENT A GVL EFFECT AND REDUCE GVHD: ALLOREACTIVITY OF
HUMAN CD19-SPECIFIC T CELLS CAN BE REDUCED BY ALLOANERGIZA-
TION WITHOUT REDUCTION OF TUMOR-SPECIFIC KILLING
Davies, J.K.1, Singh, H.3, Yuk, D.1, Champlin, R.E.4, Nadler, L.M.1,
Guinan, E.C.2, Cooper, L.J.N.3 1 Dana-Farber Cancer Institute, Boston,
MA; 2 Dana-Farber Cancer Institute, Boston, MA; 3 Children’s Cancer
Hospital, University of Texas M. D. Anderson Cancer Center, Houston,
TX; 4 University of Texas M.D. Anderson Cancer Center, Houston, TX
Redirecting specificity of human T cells to tumor antigens using
chimeric antigen receptors (CARs) is a promising approach for adop-tive cell therapy. Non-viral gene transfer of a CD19-specific CAR
into human peripheral blood mononuclear cell (PBMC)-derived T
cells using the Sleeping Beauty system is undergoing evaluation in
the autologous setting. We now are developing allogeneic CAR1 T
cells for infusion after hematopoietic stem-cell transplantation
(HSCT) to improve the graft-versus-leukemia (GvL) effect. How-
ever, CAR1 T cells possess endogenous T-cell receptors (TCR) re-
taining broad TCR Vb subfamily distribution, and may therefore
mediate alloresponses to histocompatibility antigens. Alloanergiza-
tion of donor-derived T cells (induction of alloantigen-specific hypo-
responsiveness by allostimulation with blockade of CD28-mediated
costimulation) is a simple and clinically-proven approach to selec-
tively abrogate alloresponses. We therefore assessed whether alloa-
nergization could reduce alloresponses in CAR1 T cells without
loss of CD19-specific redirected killing. Alloproliferative responses
were detected in CAR1 T cells generated from healthy donors
when co-cultured with HLA-mismatched irradiated stimulator
PBMC. To reduce potential for GvHD, CAR1T cells were alloaner-
gized by co-culture with stimulator PBMC and clinical-grade hu-
manized monoclonal anti-B7.1 and -B7.2 antibodies, resulting in
a median 75% reduction in subsequent stimulator-specific allores-
ponses without loss of proliferation to mitogenic CD3. Alloanergiza-
tion was further improved (median 93% reduction in alloresponses)
with use of CD19-depleted stimulator PBMC to remove non-allo-
specific B cell-mediated stimulation of CAR1T cells. Importantly al-
loanergized CAR1 T cells retained CD19-specific CAR expression
and CD19-specific killing. In aggregate, as allogeneic CAR1 T cells
exhibit alloproliferative responses in vitro they have potential to cause
GvHD. To overcome this potential problem, we have demonstrated
that deleterious alloresponses can be abrogated by the clinically-ap-
plicable technique of alloanergization without loss of proliferation
to mitogenic stimulus, expression of CAR, or specific killing of
CD191 targets. Thus, two techniques, CAR insertion and alloanerg-
ization, that have both achieved regulatory approval can be employed
together to produce non-alloreactive donor T cells for clinical use to
augment GvL after allogeneic HSCT for B-cell malignancies.338
IN VITRO POLARIZED TH17 CELLS INDUCE SEVERE ACUTE GRAFT-VER-
SUS-HOST DISEASE
Iclozan, C.1, Liu, C.2, Yu, Y.1, Yi, T.3, Anasetti, C.1,4, Yu, X.-Z.1,4 1 H.
Lee Moffitt Cancer Center & Research Institute, Tampa, FL; 2 University
of Florida, Gainesville, FL; 3 City of Hope National Medical Center,
Duarte, CA; 4 University of South Florida, Tampa, FL
Contribution of different T cell subsets in the development of
graft-versus-host disease (GVHD) is an active area of research. T
helper type-1 (Th1) cells were believed to be the most important
CD4 T cell subset to induce GVHD through inflammatory cyto-
kines including IFNg and TNFa. However, the concept was seri-
ously challenged by recent findings that T cells deficient for IFNg,
Stat4 or T-bet caused exacerbated GVHD. These results indicate
that Th1 subset is not required for the induction of GVHD and
other Th subsets are sufficient. Th17 is a newly identified T cell lin-
eage that secretes IL-17A among other pro-inflammatory cytokines.
Th17 cells play a critical role in autoimmune diseases, including
causing a systemic autoimmune disorder resembling GVHD. How-
ever, the role of Th17 cells in the pathogenesis of classical GVHD
remains unclear. In the current study, by transferring in vitro gener-
ated Th17 cells together with donor bone marrow into lethally irra-
diated allogeneic recipients, we demonstrated that allogeneic Th17
cells were highly pathogenic to induce GVHD, more so than naı¨ve
or Th1 controls. The same Th17 cells, however, caused no pathol-
ogy in the syngeneic recipients, indicating antigen-activation was re-
quired for these cells to induce GVHD. High potency of Th17 cells
in the induction of GVHD was correlated with their superior ability
to expand and to infiltrate in GVHD target organs. After transfer
into recipients, Th17 cells produced significant levels of IFNg and
TNFa besides IL-17A. Furthermore, IFNg KO Th17 cells had re-
duced ability to cause GVHD compared to wild type (WT) Th17
cells, indicating that IFNg also contributes to the pathogenicity of
Th17 cells. Our findings show that both Th1 and Th17 cells
participate in the pathogenesis of acute GVHD.
